Transpact Enterprises Limited is a **BSE-listed** entity (BSE Startup Platform) currently undergoing a foundational transformation. Historically a medical technology innovator, the company has pivoted its core business model toward **financial services, capital market operations, and corporate advisory**. This transition follows a **2023 change in management and ownership**, aimed at capturing growth within India’s evolving financial ecosystem. --- ### **Strategic Pivot: From MedTech to Financial Services** In **2024**, Transpact executed a definitive shift in its **Main Object Clause**, transitioning from a product-based healthcare firm to a service-oriented financial firm. * **Divestment of Legacy Assets:** To facilitate this pivot, the company entered into a **Business Transfer Agreement (BTA)** in **September 2024**. It transferred its technical know-how, software, and Intellectual Property (IP) related to its medical devices to **Transpact Medtech Private Limited**. * **Transaction Terms:** The transfer involved **no cash consideration**; instead, the purchaser assumed liabilities totaling **₹21.32 Lakhs**, offsetting assets of an equivalent value. * **Corporate Rebranding:** To reflect its new identity, the company is in the process of changing its name. Proposed titles under consideration as of **September 2025** include **ACME Fintech Limited**, **ACME Global Limited**, or **ACME Capital Ventures Limited**. --- ### **Core Business Verticals & Market Positioning** The company now operates as a **single-segment** financial services entity focused on the Indian market. Its operations are categorized into four primary pillars: | Vertical | Key Activities & Services | | :--- | :--- | | **Capital Market Services** | Acting as a **stockbroker, sub-broker, market maker, and underwriter** for shares, securities, commodities, currencies, and derivatives. | | **Investment Management** | Providing **Portfolio Management Services (PMS)**, mutual fund distribution, and comprehensive wealth management. | | **Advisory & Consulting** | Corporate finance, **debt structuring**, project appraisals, and management consulting for domestic and international clients. | | **Digital & Fund-Based** | Leveraging technology for digital trading solutions and developing fund-based activities such as **margin funding** and **loans against shares**. | The company aims to transition from a transaction-based model to a **fee-based recurring income model**, targeting both retail and institutional segments through aggressive digital adoption. --- ### **Ownership, Management, and Governance** The strategic redirection was triggered by a mandatory **Open Offer** and **Share Purchase Agreement (SPA)** completed in **mid-2023**. * **New Promoters:** **Mr. Raman Talwar** and **Mr. Kaushik Waghela** acquired a potential stake of up to **58.20%** of the equity share capital. * **Leadership:** **Mr. Raman Talwar** serves as Chairperson and Managing Director (tenure until **August 2026**). The new leadership brings over **20 years** of expertise in investment banking and private equity. * **Capital Expansion:** Shareholders have authorized an increase in borrowing limits up to **₹50 Crores** to fuel the expansion of new business lines. --- ### **Financial Performance & Outlook** Transpact has recently achieved a financial turnaround, moving from a period of consistent losses to a net profit in the most recent fiscal year. **Standalone Financial Summary:** | Particulars (₹ in lakhs) | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | | :--- | :---: | :---: | :---: | :---: | | **Total Income** | **8.25** | **0.00** | **38.25** | **17.55** | | **Net Profit / (Loss) After Tax** | **0.90** | **(6.07)** | **(6.59)** | **(22.09)** | * **Profitability:** After reporting zero income in **FY 2023-24**, the company returned to a **Net Profit of ₹0.90 lakhs** in **FY 2024-25**. * **Asset Profile:** Reflecting its new service-oriented model, the company reported **zero Property, Plant, and Equipment (PPE)** as of March 2025, maintaining a lean balance sheet. * **Solvency:** Management confirms the company’s ability to meet all current liabilities as they fall due within a **one-year period**. --- ### **Legacy MedTech Portfolio (Discontinued Operations)** While the company has divested these assets, its historical expertise was rooted in **ISO 13485:2016** certified neurodevelopmental therapy tools developed at **IIT Bombay**: * **Vestibulator:** A mechanized device for sensory integration therapy. * **Vestibulator Chair:** An at-home version for vestibular dysfunction treatment. * **Rehabsoft:** A **SaaS** cloud-based solution for clinical documentation and Individual Education Plans (IEP). --- ### **Risk Factors & Regulatory Compliance** Investors should note the following risks associated with the company’s transition and regulatory history: * **SEBI Administrative Warning (Oct 2023):** The company received a warning for historical non-compliances (**2019–2023**), including failure to correctly identify promoter group entities (specifically **Octaware Technologies Ltd.**) and incorrect disclosure of Statutory Auditors and Independent Directors. * **Execution Risk:** The shift from MedTech to Fintech involves significant execution risk, as the company must now compete in a highly regulated and crowded financial services market. * **Regulatory Environment:** The company must navigate complex **SEBI** and **RBI** regulations. Any default on loan agreements under **Section 180(1)(a)** could allow lenders to dispose of company assets or licenses. * **Quality & Liability:** Although the MedTech business is divested, any residual claims regarding **Product Recalls** or **Cost of Poor Quality (COPQ)** from legacy operations could theoretically impact reputation.